Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation: results from a phase I clinical trial.

ABSTRACT: HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation: results from a phase I clinical trial.

PROVIDER: PRJNA1023985 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26283473.fastq.gz	Fastqsanger.gz
	SRR26283474.fastq.gz	Fastqsanger.gz
	SRR26283475.fastq.gz	Fastqsanger.gz
	SRR26283476.fastq.gz	Fastqsanger.gz
	SRR26283477.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 20

Similar Datasets

HA-1-targeted T cell receptor (TCR) T cell therapy for recurrent leukemia after hematopoietic stem cell transplantation: results from a phase I clinical trial.

Project description:Tumors escape antigen-directed immunotherapies through a variety of mechanisms. We used single-cell RNA sequencing (scRNA-seq) to examine potential mechanisms of immune escape in patients with disease relapse or progression after T cell receptor T cell (TCR-T) immunotherapy directed against the minor histocompatibility antigen HA-1.

2024-01-01 | GSE244663 | GEO

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Project description:As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies. The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients. It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.

| 2172573 | ecrin-mdr-crc

Acinetobacter sp. HA strain:HA

Project description:Acinetobacter sp. HA strain:HA Genome sequencing and assembly

| PRJNA158435 | ENA

Labyrinthula sp. Ha isolate:Ha

Project description:Labyrinthula sp. Ha isolate:Ha Genome sequencing and assembly

| PRJNA607370 | ENA

RNA binding properties of PDHA2, TEX30 in testis; RNA binding properties of HA-NONO and HA-NONO△ER in 3T3L1 cell line.

Project description:To investigate the RNA binding proterties of PDHA2, TEX30 in testis; RNA binding properties of HA-NONO and HA-NONO△ER in 3T3L1 cell line, we collected wildtype testis and HA-NONO/HA-NONO△ER overexpressed 3T3L1 cells. We then performed eCLIP-seq respectively and convey subsequent bioinformatic analysis.

2024-08-08 | GSE232595 | GEO

HA-TFE3 bound regions in HK-2 HA-TFE3-inducible cells

Project description:TFE3 is a bHLH-ZIP transcription factor, which nuclear localization is regulated by a tumor suppressor FLCN. In order to analyze TFE3 occupancy in whole genome, we have generated and utilized a HK-2 HA-TFE3-inducible cell line which express HA-tagged TFE3 in a doxycycline-dependent manner. HA-TFE3 bound regions were determined by ChIPSeq.

2020-08-07 | GSE135490 | GEO

HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PRCC-TFE3-inducible HK-2 cell lines, which expresses HA-tagged TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PRCC-TFE3 by ChIPSeq.

2025-01-22 | GSE281281 | GEO

HA-PSF-TFE3 bound regions in HA-PSF-TFE3 inducible HK-2 cells

Project description:PSF-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PSF-TFE3-inducible HK-2 cell lines, which expresses HA-tagged PSF-TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PSF-TFE3 by ChIPSeq.

2025-08-18 | GSE297289 | GEO

Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC

Project description:Trial design: * Phase III, FOLFIRI versus FOLF(HA)iri (the FOLFIRI regimen with "Hyaluronic acid-Irinotecan" or "HA-Irinotecan") regimen. * Patients with mCRC (metastatic colorectal cancer), 2nd/3rd line irinotecan naïve. * Randomized 1:1, double-blinded, multi-centre, multi-national (Australia, Bulgaria, Poland, Serbia, Russia, Ukraine and the United Kingdom). * Dosing regimen: * Irinotecan (180 mg/m2) or HA-Irinotecan (180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan and HA-Irinotecan dose in must be reduced to 150 mg/m2). * Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan. * 5-fluorouracil (5-FU), 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion. * Repeat every 2 weeks for 8 months. * Patient accrual over approximately 12-14 months. * Monitoring to 18 months post-randomization. * 390 patients. * Progression Free Survival (PFS) primary endpoint. * Safety analysis on the initial 20 patients.

| 2101890 | ecrin-mdr-crc

miRNA array in the A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

Project description:We used miRNA microarrays to detail the miRNA content in A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

2024-04-18 | GSE255941 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data